Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Haemophilus influenzae

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    231 result(s) found for: Haemophilus influenzae. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005032-26 Sponsor Protocol Number: 106445, Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, randomized, controlled, multi-centre study to demonstrate the non-inferiority of the meningococcal serogroup C and the Haemophilus influenzae type b immune response of GlaxoSmith...
    Medical condition: Healthy volunteers (for primary immunization against meningococcal serogroup C and booster immunization against Haemophilus influenzae type b diseases of healthy children aged 12-18 months)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    18.0 100000004848 10070120 Haemophilus influenzae test positive LLT
    18.0 100000004862 10018953 Haemophilus influenzae meningitis LLT
    18.0 10042613 - Surgical and medical procedures 10069533 Haemophilus influenzae type b immunisation PT
    18.0 100000004848 10070124 Neisseria meningitidis test positive LLT
    18.0 100000004862 10018952 Haemophilus influenzae infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002225-22 Sponsor Protocol Number: 115373 Start Date*: 2011-11-29
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I, randomized, controlled, double-blind study to assess safety, reactogenicity and immunogenicity of GSK Biologicals’ pneumococcal vaccine 2830930A when administered as a single dose in hea...
    Medical condition: 1-dose vaccination of healthy toddlers between 12-23 months of age at the time of vaccination against Streptococcus pneumoniae (S. pn) and Haemophilus influenzae (Hi) who previously received 3 dose...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10018953 Haemophilus influenzae meningitis LLT
    14.0 10021881 - Infections and infestations 10042194 Streptococcus pneumoniae meningitis LLT
    14.0 10021881 - Infections and infestations 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    14.0 10021881 - Infections and infestations 10018954 Haemophilus influenzae secondary bacterial infection of acute bronchitis LLT
    14.0 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    14.0 10021881 - Infections and infestations 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    14.0 10021881 - Infections and infestations 10054642 Streptococcus pneumoniae septicemia LLT
    14.0 10021881 - Infections and infestations 10042195 Streptococcus pneumoniae pneumonia LLT
    14.0 10021881 - Infections and infestations 10058214 Septicaemia due to haemophilus influenzae (H. influenzae) LLT
    14.0 10021881 - Infections and infestations 10042197 Streptococcus pneumoniae septicaemia LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002898-47 Sponsor Protocol Number: 107737 Start Date*: 2007-01-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb open study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with DTPa-HBV-IPV/Hib (Infanrix h...
    Medical condition: Three dose primary vaccination of preterm infants between 8-16 weeks (56-118 days) of age at the time of first vaccination against Streptococcus pneumoniae.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-002727-15 Sponsor Protocol Number: 114174 Start Date*: 2015-06-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-type...
    Medical condition: Healthy volunteers (for one-dose vaccination of healthy children between 2-4 years of age at the time of vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae (H. ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    18.0 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    18.0 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    18.0 100000004862 10018954 Haemophilus influenzae secondary bacterial infection of acute bronchitis LLT
    18.0 100000004862 10042194 Streptococcus pneumoniae meningitis LLT
    18.0 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    18.0 100000004862 10018953 Haemophilus influenzae meningitis LLT
    18.0 100000004862 10018952 Haemophilus influenzae infection LLT
    18.0 100000004862 10058214 Septicaemia due to Haemophilus influenzae (H. influenzae) LLT
    18.0 100000004862 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005743-27 Sponsor Protocol Number: 116485,SPNG-009 Start Date*: 2012-05-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccines (2830929A and 2830930A) adminis...
    Medical condition: 3-dose primary vaccination against Streptococcus pneumoniae and Haemophilus influenzae in healthy infants between 6-12 weeks of age at the time of the first vaccination and booster vaccination at 1...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    14.1 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    14.1 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    14.1 100000004862 10042194 Streptococcus pneumoniae meningitis LLT
    14.1 100000004862 10018954 Haemophilus influenzae secondary bacterial infection of acute bronchitis LLT
    14.1 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    14.1 100000004862 10018953 Haemophilus influenzae meningitis LLT
    14.1 100000004862 10018952 Haemophilus influenzae infection LLT
    14.1 100000004862 10058214 Septicaemia due to haemophilus influenzae (H. influenzae) LLT
    14.1 100000004862 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-006066-34 Sponsor Protocol Number: 105987,105988 Start Date*: 2015-06-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-t...
    Medical condition: Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10028911 Neisseria meningitidis infection NOS LLT
    18.0 100000004862 10018953 Haemophilus influenzae meningitis LLT
    18.0 100000004862 10018952 Haemophilus influenzae infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016579-31 Sponsor Protocol Number: OVG2008/6 Start Date*: 2010-01-14
    Sponsor Name:University of Oxford
    Full Title: An open label randomised controlled study to evaluate the induction of immune memory following infant vaccination with a glyco-conjugate Neisseria meningitidis serogroup C vaccine and to assess the...
    Medical condition: Active immunisation of children for the prevention of invasive diseases caused by Neisseria meningitidis serogroup C, Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and inv...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028911 Neisseria meningitidis infection NOS LLT
    12.1 10042194 Streptococcus pneumoniae meningitis LLT
    12.1 10042195 Streptococcus pneumoniae pneumonia LLT
    12.1 10035648 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia] LLT
    12.1 10042197 Streptococcus pneumoniae septicaemia LLT
    12.1 10018952 Haemophilus influenzae infection LLT
    12.1 10018953 Haemophilus influenzae meningitis LLT
    12.1 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    12.1 10058214 Septicaemia due to haemophilus influenzae (H. influenzae) LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000943-26 Sponsor Protocol Number: 115375 Start Date*: 2011-05-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV...
    Medical condition: Healthy volunteers (Immunogenicity of the DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in terms of persistence of antibodies to diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Hib vacc...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10043376 Tetanus PT
    13.1 10021881 - Infections and infestations 10018952 Haemophilus influenzae infection LLT
    13.1 10021881 - Infections and infestations 10034738 Pertussis PT
    13.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    13.1 10021881 - Infections and infestations 10013023 Diphtheria PT
    13.1 10021881 - Infections and infestations 10036012 Poliomyelitis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2014-005136-33 Sponsor Protocol Number: V37_07 Start Date*: 2014-11-28
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Vaxem Hib to HIBERIX® Using a Local Dosing Regimen in Infants
    Medical condition: Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002140-27 Sponsor Protocol Number: 112909 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open study in children previously enrolled in study 10PN-PD-DIT-037 (111188) to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pne...
    Medical condition: Healthy volunteers (Vaccination against Streptococcus pneumoniae in healthy children previously enrolled in study 10PN-PD-DIT-037 (111188).)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005036-33 Sponsor Protocol Number: M37P1 Start Date*: 2014-11-18
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A phase I study to investigate safety and reactogenicity of Vaxem Hib in healthy children aged 16 – 20 months and infants aged 2 - 4 months.
    Medical condition: Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002076-16 Sponsor Protocol Number: 109563 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Clinical Otitis Media and Pneumonia Study (COMPAS): a phase III , double-blind, randomized, controlled, multicentre study to demonstrate the efficacy of GlaxoSmithKline (GSK) Biologicals’ 10-valent...
    Medical condition: Three dose primary vaccination of healthy infants between 6-16 weeks of age at the time of the first vaccination, followed by a booster dose at 15-18 months.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000518-19 Sponsor Protocol Number: 106672;106673;106675;106679;-80 Start Date*: 2006-04-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, open, multicentre study to assess the long-term persistence of a booster dose of GSK Biologicals? Hib-MenC conjugate vaccine compared to a booster dose of Infanrix? hexa (combined diph...
    Medical condition: The prevention of invasive diseases caused by Haemophilus influenzae type b and Neisseria meningitidis serogroup C.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    14.1 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002077-35 Sponsor Protocol Number: 111634 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled study in South Africa to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine administered as a 3-dose (6,...
    Medical condition: 3- or 2-dose primary vaccination against Streptococcus pneumoniae together with a 3-dose primary vaccination against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b di...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000254-64 Sponsor Protocol Number: 114056 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10- valent pneumococcal conjugate vaccine administered to children with sickle cell...
    Medical condition: Active immunization against disease caused by Streptococcus pneumoniae in children from 8 weeks up to 2 years of age.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    17.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001453-32 Sponsor Protocol Number: V37_07E2 Start Date*: 2015-04-29
    Sponsor Name:Novartis Vaccines and Diagnostics Srl
    Full Title: A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension study in Chinese children after a 2 + 1 dose series of either CRM197- conjugate Haemophilus influenzae type b vaccine or ...
    Medical condition: Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019730-27 Sponsor Protocol Number: 113994 Start Date*: 2010-09-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, controlled, observer-blind study to assess the safety, reactogenicity and immunogenicity of two formulations of GlaxoSmithKline (GSK) Biologicals’ Streptococcus pneumoniae p...
    Medical condition: Three-dose primary vaccination against Streptococcus pneumoniae (S pneumoniae) and Haemophilus influenzae (H influenzae) in healthy infants between 6-14 weeks (42-104 days) of age at the time of th...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.0 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000750-11 Sponsor Protocol Number: 200799 Start Date*: 2015-05-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Study to compare immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose presentation to the licensed Synflorix™ (10Pn-PD-DiT) vaccine when co-administered with DTPw-combination vaccine in healthy in...
    Medical condition: Infections, Pneumococcal
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005159-24 Sponsor Protocol Number: M37P2 Start Date*: 2014-12-23
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III, observer-blind, randomized, controlled, multi-center study to inventigate the immunogenicity and safety of the Vaxem Hib™ in 2-4 months old healthy infants in China, according to the r...
    Medical condition: Invasive Haemophilus influenzae type b disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005149-48 Sponsor Protocol Number: 111442 Start Date*: 2009-02-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III/IV, cluster-randomized, controlled study to evaluate the effectiveness of GlaxoSmithKline Biologicals’ 10-valent pneumococcal and non-typeable Haemophilus influenzae protein D conjugate...
    Medical condition: Active immunization of children from the age of 6 weeks up to 18 months of age at the time of first vaccination, against Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F an...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    14.0 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 11:36:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA